Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Privatization has to be Selective in India.

April 7, 2010

Analysis of:A ‘Private’ Affair analysing the need for private sector in Indian healthcare system | http

Privatization is a welcome option but has to be done in selective manner leaving the services for the poor untouched.

B. Braun Bypasses Bypass Surgery to be "THE" Leader in Coronary Disease Therapy.

December 13, 2009

Analysis of:B Braun launches less drug eluting balloon technology 'SeQuent Please' | www.pharmabiz.com

The Bypass surgery and angioplasty with stents are the therapies for Coronary disease today that have many disadvantages. The direct drug delivery balloons used have erratic performance hence are not favored.The Sequent Please from B. Braun, the new direct drug delivery balloon has predictable performance and no disadvantages and will be the ONLY therapy of choice for the coronary disease and B. Braun the market leader

Abbot will benefit in long run with acquisition of Evalve.

September 15, 2009

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

The acquisition will definitely have a significantly beneficial effect on the market standing as well as product portfolio of Abbot. Even though at the present time this technique developed by Evalve Inc. is useful only for a very small subset of patients, eventually Abbott can develop it further to extend it to a bigger group and therefore in the long run it will be able to win a bigger market share.

Page : 11 to 3 of 3

Subscribe to Updates

By RSS